Mega-Mergers: Largest Recent M&A Transactions
By The Online Investor Staff, updated Thu., Jan. 28, 3:50 AM
Slide #1. BridgeBio Pharma, Inc. — Eidos Therapeutics, Inc.
| Acquirer: |
BridgeBio Pharma, Inc. (BBIO) |
| Acquiree: |
Eidos Therapeutics, Inc. (EIDX) |
| Details: |
BridgeBio Pharma, Inc. ("BridgeBio") (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. ("Eidos") (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders. |
BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipelines include: BBP-265/AG10, an oral small molecule TTR, stabilizer, for the treatment of TTR amyloidosis; BBP-831/Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical AAV, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia; and BBP-454, a preclinical development program for the treatment of KRAS-driven cancers.
BBIO SEC Filing Email Alerts Service
Open the BBIO Page at The Online Investor »
BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipelines include: BBP-265/AG10, an oral small molecule TTR, stabilizer, for the treatment of TTR amyloidosis; BBP-831/Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical AAV, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia; and BBP-454, a preclinical development program for the treatment of KRAS-driven cancers.
BBIO SEC Filing Email Alerts Service
Open the EIDX Page at The Online Investor »
| Company Name: |
| BridgeBio Pharma Inc |
| Website: |
| www.bridgebio.com |
| Sector: |
| Drugs & Pharmaceuticals |
| Number of ETFs Holding BBIO: |
| 18 |
| Total Market Value Held by ETFs: |
| $562.01M |
| Total Market Capitalization: |
| $8.06B |
| % of Market Cap. Held by ETFs: |
| 6.97% |
|
| Company Name: |
| Eidos Therapeutics Inc |
| Website: |
| www.eidostx.com |
| Sector: |
| Drugs & Pharmaceuticals |
| Number of ETFs Holding EIDX: |
| 22 |
| Total Market Value Held by ETFs: |
| $191.93M |
| Total Market Capitalization: |
| $4.97B |
| % of Market Cap. Held by ETFs: |
| 3.86% |
|
Quotes delayed 20 minutes
|
